The MarketVue®: Pemphigus Vulgaris market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
Topics covered in this report:
- Disease overview: Review the disease pathophysiology and potential druggable targets
- Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
- Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
- Unmet needs: Identify opportunities to address treatment or disease management gaps
- Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
- Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing
Methodology:
Research for the MarketVue®: Pemphigus Vulgaris report is supported by 4 qualitative interviews with key opinion leaders, a quantitative survey with 20 U.S. physicians and secondary research.Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom).Key companies mentioned:
- argenx
- Cabaletta Bio
- National Institute of Allergy and Infectious Diseases (NIAID)
Key drugs mentioned:
- Rituximab
- Mycophenolate
- Azathioprine
- Cyclophosphamide
- Methotrexate
- Cyclosporine
- Tetracycline
- Dapsone
- Efgartigimod (Vyvgart)
- DSG3-CAART
- Regulatory T Cells
Table of Contents
1. DISEASE OVERVIEW- A rare, progressive autoimmune disease causing blistering of the skin and mucous membranes
- Table 1.1. Select diagnostic features of patients presenting with Pemphigus Vulgaris and Pemphigus Foliaceus
- Underlying pathophysiology dictates current and future targets for therapy
- Figure 1.1. The pathophysiology of pemphigus
- Disease definition
- Figure 2.1. Diagnosed prevalent cases of pemphigus by region in 2021
- Table 2.1 Diagnosed incident, prevalent, and drug-treated patients in the US and EU5
- Overview
- Figure 3.1. Diagnostic pathway for pemphigus patients
- Once patients reach a physician familiar with pemphigus, diagnostic testing for auto-antibodies is standard
- Figure 3.2. Dermatologist-reported percentage of pemphigus patients misdiagnosed/not diagnosed in a timely manner
- Table 3.1. Pemphigus severity classification used in clinical practice according to interviewed dermatologists
- Figure 3.3. Percentage of pemphigus patients in each PDAI severity category used in clinical trials
- Achieving complete response off long-term corticosteroid treatment is the ultimate goal
- Figure 3.4. Dermatologist-reported proportion of pemphigus patients currently treated with drug therapy
- Table 3.2. Key terms to know for pemphigus
- Table 3.3. Treatment goals for pemphigus
- Treatment flow for pemphigus
- While there is no standard approach to treatment; FDA approval of rituximab has replaced use of steroid-sparing immunosuppressants for many physicians
- Figure 3.5. Dermatologist-reported current treatment share for newly diagnosed PV and PF patients
- Figure 3.6. Dermatologist-reported proportion of pemphigus patients achieving different disease response
- Upsides and downsides of current pemphigus treatments
- Comparison of published regimens for pemphigus
- Table 3.4. Comparison of available clinical trial data for current pemphigus treatment regimens
- Physician perspectives on current treatment regimens
- Table 3.5. KOL insights on current regimens
- Upsides and downsides of rituximab
- Figure 3.7. Rituximab - upside and downside
- Figure 3.8. Dermatologist-reported % of pemphigus patients not well-managed by current treatments
- Physician perspectives on rituximab product attributes
- Key treatment dynamics that will shape disease management and drug use in pemphigus
- Figure 3.9. Important dynamics of pemphigus market evolution
- Overview
- Figure 4.1. Dermatologist-reported unmet needs in pemphigus
- The need for new PV treatments is high compared to other dermatologic conditions
- Figure 4.2. U.S. dermatologists’ rating of the need for new treatments in dermatologic conditions
- Physician insights on the most urgent unmet needs for pemphigus
- Overview
- Figure 5.1. Current vs future therapeutic goals for pemphigus
- Comparison of ongoing trials of emerging pemphigus therapies
- Table 5.1. Comparison of ongoing trials of therapies for pemphigus
- Efgartigimod is poised to be the next entrant to the pemphigus market; well-ahead of any competitors
- Figure 5.2. Phase 2 results for argenx’s efgartigimod
- Figure 5.3. Percentage of dermatologists rating CROT as “important” in a pivotal trial for a novel PV therapy
- Figure 5.4. Efgartigimod- upside and downside
- Dermatologists’ opinions on the PV pipeline
- Overview
- Table 6.1. Pemphigus therapy pricing, U.S.
- Table 6.2. Typical U.S. commercial payer coverage of rituximab and IVIg for pemphigus patients (Aetna, BCBS, Cigna, United)
- Key market access dynamics that will continue to shape treatment use
- Figure 6.1. Pemphigus patients by insurance type
- Genetech and argenx utilize patient support programs to expand access
- Figure 6.2. Strategies that could be used by Efgartigimod (SC) to compete with Rituximab (IV)
- Primary market research approach
- Epidemiology methodology
- Appendix: List of abbreviations used in pemphigus report
Companies Mentioned
- argenx
- Cabaletta Bio
- National Institute of Allergy and Infectious Diseases (NIAID)
